TY - JOUR
T1 - Detection of Metastatic Liver Disease
T2 - Use of Liver Scans and Biochemical Liver Tests
AU - Tempero, Margaret A.
AU - Petersen, Richard J.
AU - Zetterman, Rowen K.
AU - Lemon, Henry M.
AU - Gurney, Jud
PY - 1982/9/17
Y1 - 1982/9/17
N2 - The records of 94 patients with a known diagnosis of extrahepatic cancer having liver scan, biochemical liver tests (alkaline phosphatase, SGOT, lactic dehydrogenase, and bilirubin levels, and subsequent liver biopsy within a six-week period were reviewed. The sensitivity, specificity, and accuracy of the scan and biochemical tests in the detection of metastatic liver disease were calculated. The most sensitive single examination was the group of biochemical liver tests. Liver scans performed in the presence of normal biochemical test results were insensitive when compared with the liver scan alone or the liver scan in the presence of abnormal biochemical test results. The specificity and accuracy of all tests and test combinations were statistically equivalent. Screening for hepatic metastases in patients with cancer is best accomplished with the more sensitive and less expensive group of biochemical liver tests, reserving the liver scan for those patients with abnormal biochemical test results.
AB - The records of 94 patients with a known diagnosis of extrahepatic cancer having liver scan, biochemical liver tests (alkaline phosphatase, SGOT, lactic dehydrogenase, and bilirubin levels, and subsequent liver biopsy within a six-week period were reviewed. The sensitivity, specificity, and accuracy of the scan and biochemical tests in the detection of metastatic liver disease were calculated. The most sensitive single examination was the group of biochemical liver tests. Liver scans performed in the presence of normal biochemical test results were insensitive when compared with the liver scan alone or the liver scan in the presence of abnormal biochemical test results. The specificity and accuracy of all tests and test combinations were statistically equivalent. Screening for hepatic metastases in patients with cancer is best accomplished with the more sensitive and less expensive group of biochemical liver tests, reserving the liver scan for those patients with abnormal biochemical test results.
UR - http://www.scopus.com/inward/record.url?scp=84944369007&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944369007&partnerID=8YFLogxK
U2 - 10.1001/jama.1982.03330110025019
DO - 10.1001/jama.1982.03330110025019
M3 - Article
C2 - 7109154
AN - SCOPUS:84944369007
VL - 248
SP - 1329
EP - 1332
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
SN - 0002-9955
IS - 11
ER -